{"id":109259,"title":"Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.","publisher":"Share Talk","author":"sharetalk","published":"2023-08-02T08:10:40+00:00","modified":"2023-08-02T08:10:40+00:00","canonical_url":"https://www.share-talk.com/evgen-pharma-aimevg-shifts-focus-towards-more-lucrative-collaborations-as-their-partnership-with-juvlife-concludes/","markdown_url":"https://www.share-talk.com/evgen-pharma-aimevg-shifts-focus-towards-more-lucrative-collaborations-as-their-partnership-with-juvlife-concludes.md","json_url":"https://www.share-talk.com/evgen-pharma-aimevg-shifts-focus-towards-more-lucrative-collaborations-as-their-partnership-with-juvlife-concludes.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["anti-inflammatory","blood","British Lung Foundation","cancers","Charity","clinical trial","clinical trials.","COVID-19","Dr Huw Jones","Drug","Dundee","EVG","Evgen","Evgen Pharma","Huw Jones","LifeArc","patients","respiratory","Share Talk","University of Dundee"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Evgen Pharma PLC (AIM: EVG),** a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.\n\nThe deal was centred around the usage of Evgen’s Sulforadex technology, which stabilises sulforaphane, a naturally occurring compound in cruciferous vegetables like broccoli, cauliflower, kale, and cabbage.\n\nIn the fourth quarter, exclusive rights will be transferred back to Evgen, while an initial payment already submitted as part of the agreement will be retained by Evgen.\n\nEvgen’s CEO, Dr Huw Jones, mentioned that due to JuvLife’s restructuring, the rights were returned to Evgen, enabling it to concentrate on more lucrative collaborations within the pharmaceutical sector.\n\nIn late 2022, Evgen inked a licensing agreement with Stalicla and continues to progress its independent oncology programs.\n\nJones noted that the nutraceutical market, with its lower profits and oversaturation, is considerably “less appealing” for Evgen compared to the pharmaceutical market.\n\nIn another development, an Evgen partner recently received a £900,000 non-dilutive grant for researching SFX-01 in glioblastoma, a specific type of brain cancer.\n\nThe company stated its ongoing collaboration with Stalicla on an Autism Spectrum Disorder program, with the potential to generate $160.5 million in milestones and two-figure royalties.\n\nAs of 31st March 2023, Evgen held a cash reserve of £5 million. Without additional milestone payments, the existing funding runway is projected to last till the fourth quarter of next year, but future Stalica milestones could prolong this timeline till 2025."}